WO2008022278A3 - Atypical pkc mediates wnt signaling in growth cone guidance - Google Patents

Atypical pkc mediates wnt signaling in growth cone guidance Download PDF

Info

Publication number
WO2008022278A3
WO2008022278A3 PCT/US2007/076136 US2007076136W WO2008022278A3 WO 2008022278 A3 WO2008022278 A3 WO 2008022278A3 US 2007076136 W US2007076136 W US 2007076136W WO 2008022278 A3 WO2008022278 A3 WO 2008022278A3
Authority
WO
WIPO (PCT)
Prior art keywords
wnt signaling
growth cone
atypical pkc
cone guidance
disclosed
Prior art date
Application number
PCT/US2007/076136
Other languages
French (fr)
Other versions
WO2008022278A2 (en
Inventor
Yimin Zou
Original Assignee
Univ Chicago
Yimin Zou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago, Yimin Zou filed Critical Univ Chicago
Publication of WO2008022278A2 publication Critical patent/WO2008022278A2/en
Publication of WO2008022278A3 publication Critical patent/WO2008022278A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed are methods of assaying an agent for the ability to modulate the frizzled3 mediated signal transduction pathway. Also disclosed are methods of introducing a polynucleotide into a spinal cord explant. Methods of stimulating axonal turning of commissural axons are also disclosed.
PCT/US2007/076136 2006-08-16 2007-08-16 Atypical pkc mediates wnt signaling in growth cone guidance WO2008022278A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82258106P 2006-08-16 2006-08-16
US60/822,581 2006-08-16

Publications (2)

Publication Number Publication Date
WO2008022278A2 WO2008022278A2 (en) 2008-02-21
WO2008022278A3 true WO2008022278A3 (en) 2008-10-30

Family

ID=39083150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/076136 WO2008022278A2 (en) 2006-08-16 2007-08-16 Atypical pkc mediates wnt signaling in growth cone guidance

Country Status (1)

Country Link
WO (1) WO2008022278A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052203A1 (en) * 2008-11-04 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Modulating neuronal plasticity and treatment of neuronal loss by modulating wnt7a or wnt7b modulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049195A1 (en) * 2003-05-15 2005-03-03 Yimin Zou Methods and compositions for nerve regeneration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049195A1 (en) * 2003-05-15 2005-03-03 Yimin Zou Methods and compositions for nerve regeneration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCEWEN ET AL.: "Wnt Signaling: The Naked Truth?", CURRENT BIOLOGY, vol. 11, 2001, pages R524 - R526 *

Also Published As

Publication number Publication date
WO2008022278A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2007003019A3 (en) Means for functional restoration of a damaged nervous system
WO2010117470A3 (en) Nanopore sequencing devices and methods
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
GB0821929D0 (en) Percutaneous devices for separating tissue, kits and methods of using the same
WO2010080589A3 (en) Methods for screening of novel functions of receptor like kinases
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
EP2114983A4 (en) Axl tyrosine kinase inhibitors and methods of making and using the same
WO2008039841A8 (en) Signal analysis in implantable cardiac treatment devices
WO2008131396A3 (en) Dye-based ink formulations
IL186342A0 (en) Spirocyclic heterocycic derivaives and methods of their use
IL178650A0 (en) Piperidine derivatives as modulators of chemokine receptor ccr5
WO2009015037A3 (en) 5-pyridinone substituted indazoles
WO2007146057A3 (en) Screening method for modulators of viral transcription or replication
EP2046829A4 (en) Model taste cells and methods of use for identifying modulators of taste sensation
IL179729A0 (en) Novel piperidine derivates as modulators of chemokine receptor ccr5
EP2087129A4 (en) Method for identifying modulators of the nrf2-keap1-are pathway
GB2465814B (en) Method,composition and device for the treatment of enzymes and saccharides disorders
EP2378885A4 (en) 3.3.0 bicyclic glyt1 inhibitors and methods of making and using same
WO2010060099A3 (en) Wall-associated kinase-like polypeptide mediates nutritional status perception and response
WO2008027855A3 (en) Compositions and methods for modulating mtor signaling
WO2008022278A3 (en) Atypical pkc mediates wnt signaling in growth cone guidance
IL213541A0 (en) 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same
WO2008021015A3 (en) Methods of making esters of camptothecins
WO2010053522A3 (en) Methods for identifying and producing neural stem and progenitor cells and their progeny
WO2009100445A3 (en) Compositions and methods which modulate g-protein signaling for the treatment of asthma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07814176

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07814176

Country of ref document: EP

Kind code of ref document: A2